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AWARDS ABSTRACT 
Current techniques for detecting and measuring fluid flow, particularly in biological 
systems, are inadequate to effectively quanitfy the amount of flow. This ability to 
measure flow is particularly important in medical applications where blood perfusion 
in the myocardium must be determined. Existing methods generally only provide 
qualitative or semi-quantitative assessments of blood flow. 
By way of example, a microsphere contrast agent is injected into the bloodstream of 
a patient. A transducer directs ultrasonic energy into the myocardium at the resonant 
frequency of the microspheres. A second transducer directs ultrasonic energy into the 
same area at a second frequency which differs from the first frequency. The 
microspheres reaching the myocardium interact with the two ultrasonic waves and 
generate sum and difference frequencies which are indicative of the concentration of 
microspheres in the region being analyzed. 
A novel aspect of the present invention is the used of the sum and difference 
frequencies to indicate the concentration of microspheres in a region of interest. 
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Origin of the Invention
The invention described herein was jointly made by employees of
the United States Government and in the performance of work under a
NASA Contract and is subject to the provisions of Section 305 of the
National Aeronautics and Space Act of 1958, as amended, Public Law
85-568 (72 Stat. 435; 42 USC 2457).
Background of the Invention
15 1. Field of the Invention
2O
This invention relates generally to ultrasonically-reflective
microsphere contrast agents for ultrasonic imaging and more particularly
to the quantitative detection of microspheres in biological applications.
2. Description of the Related Art
25
Ultrasonically-reflective microsphere contrast agents are used in
medical ultrasonic imaging to enhance the image obtained by increasing
the contrast of and outlining the anatomic structures being studied, for
example the heart (its chambers, blood vessels, and tissue). An
example of such an agent is Albunex, available from Molecular
Biosystems, San Diego, CA. Microsphere contrast agents are also used
to ultrasonically assess adequacy of blood flow (i.e., perfusion) to the
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heart muscle (i.e., myocardium). Assessment of perfusion allows
determination of the existence or risk of a myacardial infarction (i.e., a
heart attack), in which the heart muscle dies because of blockage by
plaque of the blood vessels supplying it.
5 Currently, microsphere contrast agents must be injected directly
into the arteries of the heart muscle in order to be detectable with
conventional ultrasonic scanners (via video intensity) and to thereby
allow assessment of myacardial perfusion. Consequently, this technique
is available only during cardiac surgery or catheterization. Non-invasive
10 procedures such as peripheral intraveneous injection of the microspheres
are desirable. However, dilutional effects and trapping of the larger,
more reflective microspheres by the lung circulation lowers the effective
microsphere concentration to such a degree that conventional ultrasonic
scanners can no longer detect them in the myacardium.
15 Monaghan (U.S. Patent No. 5,255,683) discloses a method of
microsphere detection based on a shift in the radiofrequency (RF)
spectrum of the ultrasonic myocardial echo when microspheres are
present. This method is used to assess myocardial perfusion in patients.
This spectral shift method does not involve the mixing of two frequencies
20 by the microspheres with a subsequent emission of a third frequency by
the microspheres. The method disclosed by Monaghan is only a
qualitative detector of microsphere presence or absence. It does not
allow quantitative estimation of the microsphere level in the myocardium
and thus has limited use in assessing myocardial perfusion.
25 Shrope et al. in Ultrasonic Imaging 14(2), April 1992, investigated
a method of detection based on generation by the microspheres of an RF
second harmonic of the transmitted scanner frequency. As the second
harmonic generated by the myocardium is of much lower magnitude,
presence of the harmonic correlates with presence of the microspheres.
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Microsphere level in the myocardium per unit time can thus be measured
and myocardial perfusion derived. The second harmonic detection
method, however, requires that the microspheres have a fairly specific
shell type, and will currently work only with specific agents such as
SHU508 (available from the Schering Corp. in Germany).
Albert (U.S. Patent No. 4,608,993) discloses measuring blood flow
using the Doppler shift of ultrasound by blood components in a blood
vessel. However, this non-invasive technique does not use microsphere
contrast agents.
Summary of the Invention
In accordance with one aspect of the present invention, a method
and system for ultrasonically examining tissue using an ultrasonically-
15 reflective microsphere contrast agent detects the presence of ultrasonic
beat frequencies generated by the presence of the microspheres.
More specifically, in accordance with this aspect of the present
invention, a method of examining tissue using ultrasonically-reflective
microsphere contrast agents detects non-linear sum and difference beat
20 frequency signals which are produced when two signals with non-
identical frequencies are combined by mixing. The amplitude of these
beat frequencies is used to determine the concentration level of the
microspheres in the myocardium. In the myocardium, the microspheres
act as non-linear ultrasonic mixers when impinged upon by two or more
25 ultrasonic waves of different frequencies. The microspheres re-radiate
both the impinging frequencies, but in addition they generate non-linear
difference and sum frequencies. This non-linear effect is significantly
greater when one or both impinging frequencies approximates the
resonant frequency of the microspheres. Myocardial tissue, on the other
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hand, reflects the two original frequencies since the myocardium does
not generate substantial amplitudes of sum or difference frequencies.
To produce the beat frequencies, an insonifier transducer instills
ultrasonic energy into a patient's chest at a prescise single frequency,
5 ideally the resonant frequency of the microspheres. A scanner
transducer also instills ultrasonic energy into the patient's chest at a
single frequency, but the scanner frequency is different than that of the
insonifier. In addition, the scanner receives and processes the ultrasonic
echo and generates a video image. The beat frequency signal due to the
10 microspheres in the myocardial region of interest is detected within the
overall echo signal. A plot is then generated of the microsphere signal
level vs. time, which in turn correlates with myocardial perfusion.
Myocardial perfusion parameters are derived such as: time to peak of
curve, time to half peak (ascending and descending portions of curve),
15 half-time point slopes, time of appearance of contrast agent, and area
under the curve.
The present invention permits the detection of the relatively small
level of microspheres passing through the myocardium per unit of time
after peripheral intraveneous injection. In addition, the present invention
20 derives myocardial perfusion parameters from this data. Advantages of
the present invention include both the ability to quantitatively detect
small levels of microspheres in heart tissue and the ability to use this
method with all types of microsphere and microbubble contrast agents.
25 Brief Descrintinn nf the Drawing._
FIG. 1 is a block diagram of one embodiment of the present
invention in which myocardial perfusion is measured;
FIG. 2 is a typical plot of difference frequency signal amplitude
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versus time for Albunex microspheres passing through a body tissue
circulation area such as the myocardium;
FIG. 3 is a plot of difference frequency signal amplitude versus
insonifying frequency for Albunex microspheres;
5 FIG. 4 is a graphical example of the generation of sum and
difference signals by the microspheres;
FIG. 5 is a pair of scan lines showing the region analyzed
corresponding to the region of interest in the myocardium; and
FIG. 6 is a block diagram of an embodiment of the present
10 invention, including the summing circuit, with a generic interactive
volume.
Description of the Preferred Emhodiment._
15 Referring to FIG. 1, the insonifier transducer 10 instills ultrasonic
energy into a patient's chest 15 at the resonant frequency of the
microsphere contrast agent, e.g., 1.3 MHz for Albunex. The term
microsphere as used in this specification should be understood to include
the use of microbubbles. The insonifying signal originates from a signal
20 generator 20, is amplified by the RF power amplifier 30, and is then fed
to the insonifying transducer 10. The scanner transducer 40 also instills
ultrasonic energy into the patient's chest 15 at a single frequency, but
the scanner frequency is different than that of the insonifier. The
intersection of the two beams of ultrasonic energy form an intersection
25 volume which, in this example corresponds to a portion of the
myocardium 98. Typical scanner frequencies that are used in medical
applications are 1.0 MHz to 5.0 MHz, but other frequencies may also be
used. The limit on the frequency used is the attenuation of the amplitude
of the insonifying signal and the requirement that the frequency
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approximately match a resonant frequency of the microspheres. For
example, for structures close to the surface, such that attenuation of the
ultrasonic wave is not an important factor for the insonifying frequency,
frequencies ranging up to 30 Mhz could easily be used. The scanner 40
5 also receives and processes the ultrasonic echo and generates a video
image. The received image is used to locate a region of interest to
evaluate myocardial perfusion by means of the microsphere detection
method of the present invention.
Although the present invention is illustrated in reference to
10 circulation dynamics of arterial blood flow in myocardial tissue, this
apparatus and method has broader application to any body organ, body
tissue or body fluid where alteration in fluid or tissue dynamics is central
to the pathology under investigation. For example, with the use of
suitable microspheres, the present invention can be used to monitor
15 blood flow patterns in the brain of stroke patients, tumors, retinal blood
flow in the eye, tissues affected by pressure ulcers, and blood perfusion
of any tissue in any part of the human body, including muscle and
tendon tissue. Additionally, the invention can be used to enhance
images of fluids and tissue in any part of the body. The beat frequency
20 signal image can be superimposed on conventional scanning images to
reveal anatomy not otherwise visible to clinicians.
The interface electronics consist of a mixer 50, two Iowpass filters
70 and 72, a signal amplifier 80, and a lock-in amplifier 90. When
microspheres 95 are injected into the patient and reach the myocardium
25 98, the signal due to the microspheres 95 in the myocardial region of
interest is detected within the overall echo signal. A plot is then
generated of the microsphere signal level vs. time, which in turn
correlates with myocardial perfusion.
A computer 100 controls the operation of the system, plots
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microsphere concentration vs. time, and derives myocardial perfusion
parameters. Such perfusion parameters would include: time to peak of
curve, time to half peak (ascending and descending portions of curve),
half-time point slopes, time of appearance of contrast agent, and area
under the curve. FIG. 2 illustrates a typical frequency amplitude versus
time curve from which perfusion parameters can be derived.
The present invention uses ultrasonic beat frequencies generated
by the injected microspheres 95 to detect their presence and
concentration level in the myocardium 98. Beat frequencies are
produced when two signals with non-identical frequencies are combined
by mixing. Non-linear sum and difference frequencies result, according
to the following trignometric identity:
15
2O
25
Cos(A)Cos(B) = 1/2Cos(A + B) + 1/2Cos(A-B)
Referring to FIGs. 3 and 4, in the myocardium 98, the
microspheres 95 act as non-linear ultrasonic mixers when impinged upon
by two or more ultrasonic waves of different frequencies. The
microspheres re-radiate both the insonifying and the scanner frequencies,
but in addition they generate non-linear difference and sum frequencies.
This effect increases dramatically when the insonifying frequency is near
the microsphere resonant frequency. FIG. 3 shows that for Albunex, the
effect peaks markedly at about 1.3 Mhz which is the Albunex resonant
frequency. Referring to FIG. 4, if the scanner probe 40 instills fl at 2
MHz and the insonifying transducer 10 instills f2 at 1.3 MHz, the sum
(fl + f2) and difference (fl-f21 frequencies generated by the microspheres
would be 3.3 MHz and 0.7 MHz, respectively. Myocardial tissue, on the
other hand, reflects the scanner and insonifying frequencies but does not
generate significant sum or difference frequencies. Myocardial
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generation of significant sum and difference frequencies would occur
only if the insonifying frequency were near the myocardium resonant
frequency.
To determine the concentration of the microspheres, consider two
5 intersecting beams, one with a frequency fl and the other with frequency
f2, as illustrated in FIG. 4. The purpose of the measurement is to
determine at any instant the concentration of microspheres in the
insonified region, which is defined geometrically by the volume
intersection or interaction volume of the two beams. Each microsphere
10 in the interaction volume will respond by generating the mixing
components of the two frequencies, fl and f2 (fl +f2, fl-f2, 2fl, 2f 2, and to
a lesser extent, 3f_, 3f2, and other non-linear products). The magnitude
of the received signal of each mixing component depends upon A_, the
amplitude of f_, A 2, the amplitude of f2, the total number of microspheres
15 in the insonified region, and the microsphere mixing efficiency, which
depends upon microsphere properties (e.g., resonance) and acoustic
wavelengths, amplitudes, frequencies and phase relationships.
With known drive amplitudes A_ and A 2, one can use a direct
measurement with a calibrated (receive) transducer and knowledge of the
20 tissue attenuations in the respective insonifying beam paths to determine
the concentration of microspheres in the interaction volume. One way is
to develop a tissue phantom which is placed between the drive
transducers and the difference frequency sensing device. When the
drive transducers are activated with specific drive waveforms, the
25 calibration is made from measurements of the mixed frequencies from a
known concentration of microspheres in the interaction volume. With a
determination of the size of the insonified volume in the patient, the only
unknown is the actual microsphere concentration, which therefore can be
calculated from measurement and comparison with the calibration
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results. The larger the amplitude of the insonifying waves, the greater is
the amplitude of the detected wave and therefore the quicker the scan
that can be performed.
The frequency fl-f2 would be the lowest frequency component,
5 and hence it would most likely be the most easily received of the mixing
components, since it would be the least affected by tissue attenuation.
Therefore, it will be used to illustrate the prresent invention, although any
mixing component could be used. Once the difference frequency is
generated, it must traverse the tissue between the generating
10 microsphere and the transducer or transducer array. The output from
this transducer is analyzed to determine microsphere concentration. This
analysis can be done by computer algorithm or other analytical means.
The microspheres in the interaction volume of the two ultrasonic waves,
each wave at its respective drive frequency, will be appropriately
15 activated.
The frequencies fl and f2 are chosen (1) so that either fl or f2
approximates the resonant frequency of the microspheres but differs
from the resonant frequency of the tissue to be examined and (2) so that
the output of the difference frequency receiver transducer is maximized.
20 Other considerations which affect the decision are tissue attenuation to fl
and f2, distance of activation volume from the fl and f2 drive transducers,
location of the difference frequency transducer, and the efficiency of
microsphere generation of the difference frequency fl-f2.
For example, if one is examining a region near the junction of
25 muscle fibers to the tendon which attaches the muscle to the bone, the
drive transducers could be spaced 60 ° apart on the arc of a circle where
the area under examination is located at the center. The receiver
transducer, sensitive to the difference frequency fl-f2, can be placed on
the same circle but located 150 ° from either inonifying transducer. Under
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these conditions, the ultrasonic waves generated by the insonifying
transducers intersect at the area in question and the wave of frequency
fl-f2 generated by the microspheres will propagate from the insonified
volume at the center of the circle to the receive transducer. The output
5 of the receive transducer is then proportional to the concentration of
microspheres within the insonified volume.
After the selection of the drive frequencies, the receive transducer
is chosen to optimize the sensitivity to the drive frequency. The order of
importance in selecting the drive frequencies will be largely determined
10 by the particular application. For example, if the region to be examined
is approximately 5 cm deep and the receive transducer is placed directly
below the area of examination, the following factors will be important in
selecting the drive frequencies: (1) the efficiency of mixing of the two
insonifying ultrasonic waves by the microspheres, (2) the attenuation of
15 neighboring tissue through which the insonifying ultrasonic waves must
pass to reach the interaction volume, (3) the depth of the interaction
volume from the drive transducers, and (4) an acceptable site location for
the receive transducer.
A high-gain, extremely narrow-band amplifier circuit 90 (lock-in
20 amplifier) detects precisely the difference frequency generated by the
microspheres 95. It does this by comparing the incoming RF signal to an
exact difference reference signal derived from electronically mixing the
scanner transmit frequency and the chest insonifying frequency and
Iowpass filtering the result. The incoming RF echo signal contains both
25 the myocardial tissue signal and the microsphere-generated signal
consisting of the scanner, insonifying, sum and difference signals. The
incoming RF echo signal also contains noise. A Iowpass filter 72 is used
to allow passage of only the difference frequency and the low frequency
component of the noise to the lock-in amplifier circuit input. The lock-in
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amplifier circuit function can be understood by the following:
5
Let:
Acos(X)
signal)
= electronically-generated difference signal (reference
10
[Bcos(Y) + n(t)] = microsphere-generated difference signal
(desired signal) plus noise, which constitutes the Iowpass filtered
incoming RF signal.
The lock-in circuit 90 first electronically mixes the Iowpass filtered
incoming RF signal with the reference signal:
Acos(X)[BCos(Y) + n(t)] = 1/2ABCos(X + Y) + 1/2 ABCos (X- Y)
15 + n(t)ACos(X)
If X = Y, then:
20
= 1/2ABCos(2X) + 1/2AB + n(t)ACos(X)
Lowpass filtering the result gives:
= 1/2AB
25 i.e., a DC value which is proportional to the amplitudes of the reference
signal and the desired microsphere signal.
If the reference amplitude is held constant, then the result is a DC
value proportional to only the microsphere-generated difference signal.
The lock-in amplifier circuit 90 can detect the microsphere signal even
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when the incoming RF signal is highly contaminated with noise of much
greater amplitude. The lock-in function can be accomplished by either
analog or digital (i.e., software) means. The output of the lock-in
amplifier 90 consists of the amplitude of the microsphere difference
5 frequency detected. Detection of the signal due to the microspheres is
thus possible even at very low concentrations such as in the myocardium
after peripheral intravenous injection.
Referring to FIG. 5, only a portion of the RF sector scan lines is
analyzed, corresponding to the region of interest in the myocardium.
10 Peaks corresponding to the transducer burst 120, anterior wall echo 130,
and the posterior wall echo 140 are present in both scans. However,
only the scan in which the contrast agent is present indicates
microsphere RF echos 150.
Referring to FIG. 6, since fl and f2 are relatively close to each
15 other, it is ppossible to use a single transducer 110. The intersection
volume here is a cylinder 105 coaxially located beneath a single drive
transducer. For this application it is possible to form an electrical drive
signal by employing a summing circuit 60 to electrically add two
electrical sine waves of different frequencies (fl, f2) together to form the
20 electrical drive voltage.
Although the present invention has been illustrated with reference
to human applications, it should be understood by those skilled in the art
of ultrasonic imaging that the present invention could also be used in a
variety of applications in which the ultrasonoc detection of fluids is
25 contemplated. For example, the present invention could be used in
animals, plant systems and in a variety of industrial flow processes.
Many modifications, improvements and substitutions will be
apparent to the skilled artisan in view of the foregoing description
without departing from the spirit and scope of the present invention as
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described in the specification and defined in the following claims. Thus,
it is to be understood that, within the scope of the appended claims, the
invention may be practiced other than as specifically described
hereinabove.
What is claimed is:
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BEAT FREQUENCYULTRASONIC MICROSPHERE
CONTRAST AGENT DETECTIONSYSTEM
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Abstract of the. Disclosure.
A system for and method of detecting and measuring
concentrations of an ultrasonically-reflective microsphere contrast agent
involving detecting non-linear sum and difference beat frequencies
produced by the microspheres when two impinging signals with non-
identical frequencies are combined by mixing. These beat frequencies
can be used for a variety of applications such as detecting the presence
of and measuring the flow rates of biological fluids and industrial liquids,
including determining the concentration level of microspheres in the
myocardium.
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